companydata.dkcompanydata.dk

Ascendis Pharma Oncology Division A/S: Financial statements 2020

CVR: 41034076

Source: annual report 2020, Danish Business Authority

13/12/2019 – 31/12/2020

Ascendis Pharma Oncology Division A/S (CVR 41034076) has filed annual accounts for 2020. In 2020, the company reported a gross profit of EUR -35,705,202 and a net result of EUR -36,079,781. Equity in the 2020 report amounted to EUR -28,128,419.

Gross Profit
EUR -35,705,202
Profit/Loss
EUR -36,079,781
Equity
EUR -28,128,419
Total Assets
EUR 8,469,083
Employees
0

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is Ascendis Pharma Oncology Division A/S?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

About Ascendis Pharma Oncology Division A/S

Ascendis Pharma Oncology Division A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR -85,226,000 and a net result of EUR -110,131,000 compared with EUR -106,375,000 the year before. Equity in the 2025 report amounted to EUR -501,637,000.

Source: annual report 2025, Danish Business Authority

Other financial years